LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

Core Insights - LB Pharmaceuticals Inc announced the presentation of three posters at the 38th European College of Neuropsychopharmacology Congress, focusing on the Phase 2 NOVA clinical trial of LB-102 for acute schizophrenia [1][3] Group 1: Clinical Trial Findings - The analysis of LB-102's effects on cognition in patients with acute schizophrenia showed a significant treatment effect size compared to placebo, with values of 0.26 (p=0.0476) at 50 mg, 0.41 (p=0.0027) at 75 mg, and 0.66 (p=0.0018) at 100 mg after four weeks of treatment [2][4] - The NOVA trial was a randomized, double-blind, placebo-controlled study involving 359 adults aged 18 to 55, assessing the efficacy and safety of LB-102 over four weeks [9] Group 2: Additional Presentations - In addition to cognitive findings, the company will present primary efficacy and safety results from the NOVA trial and a post-hoc analysis on negative symptoms in patients with prominent negative symptoms at baseline [3][4] - The posters will be available on the LB Pharmaceuticals website starting October 11, 2025 [7] Group 3: Product Overview - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing statistically significant benefits versus placebo in the Phase 2 trial, with a favorable safety profile and positive effects on negative symptoms and cognition [10][11] - The company is exploring further indications for LB-102, including bipolar depression, major depressive disorder, and Alzheimer's disease psychosis [10]